Form 4: BeiGene Director Margaret Dugan Reports Acquisition of Shares and Options

Director Margaret Dugan reports acquisition of BeiGene shares and options, including restricted share units and share options, under the company's Independent Director Compensation Policy.

Summary

• Margaret Dugan, a director of BeiGene, Ltd., reported changes in beneficial ownership of the company's securities.
• On May 21, 2025, Dugan acquired 10,985 ordinary shares, representing securities underlying restricted share units, at a price of $0.
• Following the transaction, Dugan beneficially owns 56,940 ordinary shares.
• Dugan also acquired 22,750 share options with an exercise price of $18.19, exercisable on the earlier of the first anniversary of the grant date or the next annual general meeting, expiring on May 20, 2035.
• These options are also subject to accelerated vesting upon a change in control or certain termination events.
• The restricted share units and options were granted under BeiGene's Independent Director Compensation Policy, as amended.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence in the company, but it's a routine disclosure.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future.
• The vesting terms of the restricted share units and options incentivize long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting and exercisability of the shares and options are tied to future events such as the annual general meeting and potential change in control.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in the holdings of a key company director.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash, equity, and options to align the interests of directors with those of shareholders.
• The vesting schedules and terms described in the document are typical for director equity grants in publicly traded companies.
• Similar filings can be compared across the biotechnology industry to assess the relative compensation and equity ownership of directors in peer companies such as Amgen, Gilead Sciences, and Regeneron.

Stakeholder Impact

• The acquisition of shares by a director can be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.
• The terms of the equity grants may incentivize the director to contribute to the long-term success of the company.

Key Dates

Keywords

BeiGene, Director, Margaret Dugan, Form 4, Beneficial Ownership, Ordinary Shares, Share Options, Restricted Share Units, Independent Director Compensation Policy